Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
601
-
Total 13F shares, excl. options
-
238M
-
Shares change
-
+1.94M
-
Total reported value, excl. options
-
$36.1B
-
Value change
-
+$313M
-
Put/Call ratio
-
0.74
-
Number of buys
-
339
-
Number of sells
-
-219
-
Price
-
$152.04
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q3 2017
683 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q3 2017.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 601 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 238M shares
of 257M outstanding shares and own 92.63% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (26.5M shares), BlackRock Inc. (19.7M shares), VANGUARD GROUP INC (17.6M shares), FMR LLC (16.6M shares), WELLINGTON MANAGEMENT GROUP LLP (13.3M shares), Capital World Investors (11.6M shares), STATE STREET CORP (11.2M shares), JPMORGAN CHASE & CO (9.32M shares), Clearbridge Investments, LLC (7.08M shares), and JENNISON ASSOCIATES LLC (6.02M shares).
This table shows the top 601 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.